Global First Approval For Daiichi’s EZH1/2 Inhibitor Valemetostat In Japan
Ozoralizumab Also Gets First Nod
Japan has granted to the first approval worldwide to Daiichi Sankyo’s dual EZH1/2 inhibitor valemetostat, for the treatment of adult T-cell leukemia/lymphoma. Taisho’s trivalent anti-TNFα nanobody ozoralizumab also received its global first approval, as part a large new batch of regulatory nods in the country.
You may also be interested in...
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
The Japanese and German firms agree to establish a joint company to handle 13 mature brands from Kyowa Kirin's portfolio, mainly focused on pain management and including Abstral and PecFent. Grünenthal will own 51% and plans to fully buy out the operation in early 2026.